Zogenix Gets $51M In Series B

San Diego-based Zogenix, a pharmaceutical firm developing treatments for neuroscience disorders and pain, said Wednesday that it has completed a $51M, Series B preferred stock financing. The firm said that the round was led by Clarus Ventures and Domain Associates, and also included prior investors Scale Venture Partners, Thomas, McNerney & Partners, and Abingworth Management and new investor Oxford Finance Corporation. The firm said that $36M of the funding has been received, with $15M available to the firm for use between December 2009 and February 2010. Zogenix will use the funding to launch its first product, SUMAVEL DosePro, and hire staff to bring the company's total size to over 105 people.